UroGen Pharma Ltd. (URGN) income statement
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$27.65−4.08 (-12.86%)
Close on Nov 20, 2026Market cap $1.35BP/E –Yield –
UroGen Pharma Ltd. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 90.8%
- Operating margin
- -35.3%
- Net margin
- -51.7%
- Return on equity, FY2025
- 268.6%
Financial strength
- Current ratio
- 3.80
- Debt to equity
- -1.43
- Debt to assets
- 74.7%
- Cash to current liabilities
- 127.8%
Valuation
- P/E ratio
- –
- Price to sales
- 7.16
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?